What is Pathalys Pharma?
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company dedicated to the advancement of multiple therapeutic candidates aimed at addressing significant unmet needs in the management of End-Stage Kidney Disease (ESKD). The company's commitment lies in developing innovative treatments that can improve the quality of life for patients suffering from this debilitating condition. By focusing on late-stage clinical development, Pathalys Pharma is strategically positioned to bring its promising therapies closer to market, leveraging its scientific expertise and robust clinical trial data to demonstrate efficacy and safety.
How much funding has Pathalys Pharma raised?
Pathalys Pharma has raised a total of $255M across 2 funding rounds:
Debt
$150M
Series B
$105M
Debt (2023): $150M with participation from DaVita, OrbiMed, Abingworth, Catalys Pacific, and Carlyle
Series B (2024): $105M led by TCG Crossover, Samsara BioCapital, and Catalys Pacific
Key Investors in Pathalys Pharma
TCG Crossover
TCG Crossover (TCGX) is a science-driven investment firm focused on advancing disruptive medicines, aiming to invest in breakthrough therapies that have the potential to transform healthcare. They support the development of extraordinary medical solutions within the pharmaceutical and biotechnology sectors.
Samsara BioCapital
Samsara BioCapital focuses on investing to create transformative therapeutics for patients, partnering with scientists and drug developers to support the next generation of therapeutic breakthroughs. They aim to drive innovation in the biopharmaceutical sector.
Catalys Pacific
Catalys Pacific transforms life sciences innovation by creating and investing in global biotech companies, specializing in targeted therapies for conditions like hypertension and chronic kidney disease. They emphasize early-stage investment and transpacific partnerships to improve patient lives.
What's next for Pathalys Pharma?
With the recent infusion of capital, Pathalys Pharma is poised to accelerate its development programs and potentially expand its therapeutic portfolio. The major strategic investment indicates strong backing for the company's ongoing clinical trials and future commercialization efforts. This financing is expected to fuel the progression of its lead candidates through regulatory approval processes and support the scaling of its operational infrastructure. The company's focus on ESKD, a condition with a substantial patient population and limited treatment options, presents a significant market opportunity. Pathalys Pharma's strategic use of this capital will be critical in navigating the complexities of drug development and market entry, aiming to solidify its position as a key player in the nephrology therapeutic space.
See full Pathalys Pharma company page
